Skip to main content
  • Home
  •  Christie Ballantyne
Christie Ballantyne

Christie Ballantyne

Chief of Cardiovascular Research and Director of the Center for Cardiometabolic Disease Prevention

Baylor College of Medicine, Houston, Texas

Biography

Dr Christie Ballantyne is the Chief of Cardiovascular Research, Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine at Baylor College of Medicine in Texas, US.

He received his MD from Baylor College of Medicine and performed both his internal medicine residency at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

Dr Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions, translational research in biomarkers and clinical trials.


Over the past 30+ years, his many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognised Christie as one of “The World's Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr Ballantyne as a “Highly Cited Researcher” in 2017, 2018 and 2019 for being in the top 1% of researchers most cited. In 2019, Dr Ballantyne was awarded the Baylor College of Medicine Michael E. DeBakey, M.D., Excellence in Research Award. His research in biomarkers has led to the FDA approval of 2 biomarkers for risk prediction of cardiovascular disease and he has played a prominent role in the clinical development and FDA approval of new therapies for treatment of lipids and prevention of heart disease.